ISRG

Business profile & competitive position

Intuitive Surgical, Inc. (ISRG) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. Its business centers on robotic-assisted surgical platforms—most visibly the da Vinci system—which surgeons use for minimally invasive procedures spanning urology, gynecology, thoracic surgery, and general surgery. Revenue typically comes from a combination of system placements, recurring instrument and accessory sales, and ongoing service contracts.

The raw profitability metrics support the picture of a company with meaningful pricing power. A 28.4% net margin is well above what most capital-equipment manufacturers sustain, and a 17.8% return on equity (ROE) shows that shareholders’ capital is being converted into profits at a healthy clip. Those two figures together are consistent with an economic moat built on a durable, razor-and-blade-style ecosystem: once a hospital adopts a robotic platform, the recurring consumables and service revenue tend to carry high attach rates and stable pricing. That said, the same numbers do not prove an unassailable monopoly. The Medical - Instruments & Supplies industry remains competitive, and regulators, payers, and rival technologies can all erode margin over time.

Financial posture

As of the snapshot, ISRG carried a $140.7 billion market capitalization, traded at a 45.0 P/E ratio, and posted a beta of 1.47. The company is therefore priced as a large-cap growth compounder, not a cheap value stock. A P/E of 45 implies the market is baking in many years of above-average earnings expansion; compared with the broader S&P 500, that is a meaningful premium and leaves limited room for operational disappointment.

The valuation premium sits on top of genuinely strong fundamentals. The 28.4% net margin gives management a cushion against supply-chain cost pressure or pricing headwinds, while the 17.8% ROE indicates the business is generating respectable returns without relying on extreme financial leverage. The 1.47 beta simply warns that the stock has historically moved roughly 47% more than the overall market in either direction, which is important context for anyone sizing a position around events such as earnings. The stock was last at $398.255, with an RSI of 63.3 and a 50-day EMA of $381.69—neither deeply overbought nor obviously distressed.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company, ISRG’s risk map is dominated by factors that affect the broader medical-device industry rather than idiosyncratic company issues. Regulatory approvals and clearances are critical in every major market: the U.S. FDA, the EU’s CE/MDR process, and equivalent agencies in Asia all determine where a system or indication can be sold. The recent EU nod to expand da Vinci SP in gynecologic procedures, reported on September 16, 2026, is a textbook example of how regulatory access directly widens the addressable market.

Other industry-wide exposures include reimbursement policy from Medicare, Medicaid, and private insurers; hospital capital-expenditure cycles, which tighten or loosen when interest rates and budgets shift; trade policy and tariffs on electronics, optics, motors, and other imported components; currency translation for overseas revenue; and supply-chain reliability for precision hardware. Litigation and patent disputes are also common in the medical-technology space, as is long-term political pressure on healthcare pricing. None of these are unique to Intuitive, but the sector classification tells you they are the right risks to watch.

Recent developments

• September 16, 2026 (zacks.com): “ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures.” The clearance should allow more European centers to use the single-port system across additional gynecologic indications, potentially supporting system utilization and procedure growth.
• September 15, 2026 (zacks.com): “ISRG’s da Vinci Study Shows Better Outcomes Across 13 Common Conditions.” Clinical real-world evidence matters heavily in this industry because it can influence both surgeon adoption and payer willingness to reimburse robotic-assisted surgery.
• September 16, 2026 (zacks.com): “Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know.” A reminder that news-driven retail and institutional attention can exaggerate near-term price swings.
• September 14, 2026 (zacks.com): “Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key Facts.” The stock outperformed on that day, consistent with its above-market beta.

Earnings behavior & post-earnings drift

ISRG’s recent earnings record looks close to flawless on the surface. Over the last eight reported quarters, the company beat consensus estimates 8 out of 8 times (100% beat rate), with an average earnings surprise of 14.1%. Yet the post-earnings price reaction has been anything but a straight line. The average 5-day move after earnings across those quarters was just 0.08%, classified as flat. That is the key disconnect: beating estimates has not reliably produced a sustained pop.

The last four reports illustrate the dichotomy clearly. On July 16, 2026, ISRG reported $2.80 EPS versus a $2.48 estimate, a 12.9% surprise—but the stock fell -14.15% the next day and -17.48% over the following five days. Three months earlier, on April 21, 2026, the company delivered $2.80 against $2.51 (an 11.6% beat), and the stock rose 7.16% the next day and 3.40% over five days. On January 22, 2026, ISRG beat by 11.5% with $2.53 versus $2.27, yet the stock slipped -0.35% the next day and -3.47% over five sessions. The strongest reaction came on October 21, 2025, when a 20.6% beat ($2.40 actual versus $1.99 estimate) drove a 13.89% one-day rally and a 17.86% five-day gain.

Because the average five-day drift is essentially zero, it is fair to say the unofficial consensus is sometimes higher than the published estimate, and guidance, commentary, valuation positioning, or the macro backdrop can easily overshadow a headline beat. The next scheduled report is October 20, 2026 after the close, with a consensus EPS estimate of $2.64.

For a deeper dive into how sell-side and institutional models are currently positioned around Intuitive Surgical—beyond the headline numbers and near-term news flow—look at the full institutional verdict.